Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female aged 18 and above.~* The body mass index is in the range of 18.6-28.5 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.~* The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test.~* The subjects have no family planning within 3 months and could select contraceptive method.~* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.~Exclusion Criteria:~* Being allergy to the study medications, smoking, alcohol abuse.~* Participation in another clinical trial within 3 months.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Amlodipine (Type: ACTIVE_COMPARATOR): amlodipine reference formulation at a single dose of 10 mg
- Levamlodipine (Type: EXPERIMENTAL): levamlodipine test formulation at a single dose of 5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).